alexa Comparative Study of Lornoxicam and Diclofenac in Patie
ISSN: 2319-9865

Research & Reviews: Journal of Medical and Health Sciences
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Comparative Study of Lornoxicam and Diclofenac in Patients Suffering from Osteoarthritis

Shailesh Yadav1*, Shalini Salwan2, Ajay MittalM3, Manoj Goyal1 and Poonam Salwan4

1Department of Pharmacology, MMIMSR, Mullana, Ambala, Haryana, India

2Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab, India

3Department of Medicine, MMIMSR, Mullana, Ambala, Haryana, India

4Department of Pharmacology, SGT Institute of Medical Sciences and Research, Gurgaon, India

*Corresponding Author:
Shailesh Yadav
Department of Pharmacolog
MMIMSR, Mullana, Ambala
Haryana, India

Received: 06 February 2014 Accepted: 25 March 2014



Lornoxicam is comparatively a newer NSAID. This study was done to compare the efficacy and tolerability of lornoxicam and diclofenac in the treatment of patients suffering from osteoarthritis over 32 weeks. A randomized, open, parallel-group trial of patients with OA of knee enrolled 223 patients. Out of 223 patients enrolled 216 patients participated in the study. The available patients were randomly divided into two groups. One group of 108 patients received lornoxicam 4-8 mg BID. for 32 weeks, another group of 108 patients received diclofenac 50-100 mg TID. for 32 weeks. Assessments were made at baseline, 4 weeks, 8 weeks and then every 10 weeks. They comprised pain score, adverse reactions and withdrawals. The VAS score was reduced in lornoxicam group by 22.51% and 19.16% in diclofenac group. These values were significant from baseline values in both the groups and reduction in lornoxicam group was significant in comparison to diclofenac group. During the next 22 weeks pain intensity continued to decrease but this reduction was not significant. The adverse events were significantly less in the lornoxicam group in comparison to diclofenac group. Lornoxicam 4-8 mg bid was more effective as analgesic in comparison to diclofenac 50-100 mg TID. The lornoxicam was tolerated better than diclofenac. Thus, lornoxicam appears to be a useful therapeutic alternative to diclofenac in patients suffering from osteoarthritis.


Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version